Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE FL-2
2023-506906-38-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial of epcoritamab, rituximab and lenalidomide in follicular lymphoma (FL) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Complete response rate at 30 months. Planned start May 2024; status: authorised.
02
Drugs
epcoritamabrituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-506906-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506906-38-00.